It is now well established that cancer cells co-exist within a complex environment with
stromal cells and depend for their growth and dissemination on tight and plastic interactions …

Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or
cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal …

The emergence of immune checkpoint inhibitors for the treatment of cancer has led to major
changes to the therapeutic landscape of lung cancer. Improvements in overall survival …

In theranostics, radiolabeled compounds are used to determine a treatment strategy by
combining therapeutics and diagnostics in the same agent. Monoclonal antibodies (mAbs) …

Characterizing the molecular immune subtype and micro-environment of lung cancer is
necessary to understand immunogenic interactions between infiltrating immune and stromal …

Aim: In this meta-analysis, we evaluated several predictors of benefit to single-agent
immune checkpoint inhibitors (ICIs) in metastatic non-small-cell lung cancer (NSCLC) …

Objectives The associations between the neutrophil-lymphocyte ratio (NLR) and platelet-to-
lymphocyte ratio (PLR) with the responses of non-small cell lung cancer (NSCLC) patients …

Immune checkpoint inhibitors have gained an established role in the treatment of different
tumors. Indeed, their use has dramatically changed the landscape of cancer care, especially …

There is growing evidence that molecular subtypes (eg luminal and basal subtypes) affect
the prognosis and treatment response in patients with muscle invasive urinary bladder …

Recent efforts on genome wide profiling of muscle invasive bladder cancer (MIBC) have led
to its classification into distinct genomic and transcriptomic molecular subtypes that exhibit …